RT Journal Article
SR Electronic
T1 Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.30.21256413
DO 10.1101/2021.04.30.21256413
A1 Badenoch, James B.
A1 Rengasamy, Emma R.
A1 Watson, Cameron J.
A1 Jansen, Katrin
A1 Chakraborty, Stuti
A1 Sundaram, Ritika D.
A1 Hafeez, Danish
A1 Burchill, Ella
A1 Saini, Aman
A1 Thomas, Lucretia
A1 Cross, Benjamin
A1 Hunt, Camille K.
A1 Conti, Isabella
A1 Ralovska, Sylvia
A1 Hussain, Zain
A1 Butler, Matthew
A1 Pollak, Thomas A.
A1 Koychev, Ivan
A1 Michael, Benedict D.
A1 Holling, Heinz
A1 Nicholson, Timothy R.
A1 Rogers, Jonathan P.
A1 Rooney, Alasdair G.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/05/04/2021.04.30.21256413.abstract
AB Background The nature and extent of persistent neuropsychiatric symptoms after COVID-19 are not established. To help inform mental health service planning in the pandemic recovery phase, we systematically determined the prevalence of neuropsychiatric symptoms in survivors of COVID-19.Methods For this pre-registered systematic review and meta-analysis (PROSPERO ID CRD42021239750) we searched PubMed, EMBASE, CINAHL and PsycINFO to 20th February 2021, plus our own curated database. We included peer-reviewed studies reporting neuropsychiatric symptoms at post-acute or later time-points after COVID-19 infection, and in control groups where available. For each study a minimum of two authors extracted summary data. For each symptom we calculated a primary pooled prevalence using generalised linear mixed models. Heterogeneity was measured with I2. Subgroup analyses were conducted for COVID-19 hospitalisation, severity, and duration of follow-up.Findings From 2,844 unique titles we included 51 studies (n=18,917 patients). The mean duration of follow-up after COVID-19 was 77 days (range 14-182 days). Study quality was generally moderate. The most frequent neuropsychiatric symptom was sleep disturbance (pooled prevalence=27·4% [95%CI 21·4- 34·4%]), followed by fatigue (24·4% [17·5-32·9%]), objective cognitive impairment (20·2% [10·3-35·7%]), anxiety (19·1%[13·3-26·8%]), and post-traumatic stress (15·7% [9·9-24·1%]). Only two studies reported symptoms in control groups, both reporting higher frequencies in Covid-19 survivors versus controls. Between-study heterogeneity was high (I2=79·6%-98·6%). There was little or no evidence of differential symptom prevalence based on hospitalisation status, severity, or follow-up duration.Interpretation Neuropsychiatric symptoms are common and persistent after recovery from COVID-19. The literature on longer-term consequences is still maturing, but indicates a particularly high frequency of insomnia, fatigue, cognitive impairment, and anxiety disorders in the first six months after infection.Funding JPR is supported by the Wellcome Trust (102186/B/13/Z).IK is funded through the NIHR (Oxford Health Biomedical Research Facility, Development and Skills Enhancement Award) and the Medical Research Council (Dementias Platform UK and Deep and Frequent Phenotyping study project grants).HH is funded by the German Research Foundation (DFG, Grant: HO 1286/16-1). The funders played no role in the design, analysis or decision to publish.Evidence before this study Neuropsychiatric symptoms like cognitive impairment, fatigue, insomnia, depression and anxiety can be highly disabling. Recently there has been increasing awareness of persistent neuropsychiatric symptoms after COVID-19 infection, but a systematic synthesis of these symptoms is not available. In this review we searched five databases up to 20th February 2021, to establish the pooled prevalence of individual neuropsychiatric symptoms up to six months after COVID-19.Added value of this study This study establishes which of a range of neuropsychiatric symptoms are the most common after COVID-19. We found high rates in general, with little convincing evidence that these symptoms lessen in frequency during the follow-up periods studied.Implications Persistent neuropsychiatric symptoms are common and appear to be limited neither to the post-acute phase, nor to recovery only from severe COVID-19. Our results imply that health services should plan for high rates of requirement for multidisciplinary services (including neurological, neuropsychiatric and psychological management) as populations recover from the COVID-19 pandemic.Competing Interest StatementJPR held one advisory meeting with representatives from Promentis Pharmaceuticals regarding drug development. No payment was made. JPR received payment from Alberta Psychiatric Association for lecturing at the Annual Scientific Conference. IK receives a contribution towards his salary from the Medical Research Council (Dementias Platform UK grant), NIHR Oxford Health Biomedical Research Centre, NIHR Development and Skills Enhancement award. IK has received the following grants: Medical Research Council Deep and Frequent Phenotyping study project grant, Oxford Global Challenges Research Fund project grant, MRC-NIH Partnership in Neurodegeneration award. IK has received consulting fees from Mantrah Ltd, Sharp Tx Ltd, Cognetivity Ltd. He has served as an advisory board member and has stocks options in Mantrah Ltd and Sharp Tx Ltd.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=239750 Funding StatementJPR is supported by the Wellcome Trust (102186/B/13/Z). IK is funded through the NIHR (Oxford Health Biomedical Research Facility, Development and Skills Enhancement Award) and the Medical Research Council (Dementias Platform UK and Deep and Frequent Phenotyping study project grants). HH is funded by the German Research Foundation (DFG, Grant: HO 1286/16-1). The funders played no role in the design, analysis or decision to publish. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A systematic reviewAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur full R code, and data, can be made available on reasonable request.